Contact this trialFirst, we need to learn more about you.
Oral GB2064 for Myelofibrosis
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing a new medication called GB2064, which blocks a protein known as LOXL-2. It is aimed at patients with Myelofibrosis, a condition where the bone marrow becomes scarred. By blocking LOXL-2, the medication hopes to reduce this scarring and improve symptoms.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service